CANCER

articles with this tag

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

READ ARTICLE

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

READ ARTICLE

GTG Validates Cancer Tests As it Looks to Global Expansion

GTG Validates Cancer Tests As it Looks to Global Expansion

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

READ ARTICLE

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

READ ARTICLE

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

READ ARTICLE

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

READ ARTICLE

Thanks for subscribing!

X